Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration has not been studied. Mycophenolate is mainly glucuronidated by UGT1A9 and UGT2B7 and in vitro data suggest that mycophenolic acid (active metabolite) inhibits the renal transporters OAT1/OAT3. A clinically significant interaction with emtricitabine is unlikely. However, concentrations of both tenofovir and mycophenolate could be increased due to competition for active tubular secretion. Closely monitor renal function due to the risk of tubular necrosis that may occur with both tenofovir and mycophenolate.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking